Abstract
The ten-eleven translocation enzymes catalyze the conversion of 5-methylcytosine to 5-hydroxymethylcytosine, a distinct epigenetic mark that has an integral role in active demethylation. Genes that regulate the distribution and amount of 5-hydroxymethylcytosine in the genome could be suitable therapeutic targets to correct abnormal methylation in cancer. Here, we present an overview of the role of the 5-hydroxymethylcytosine pathway in human disease and discuss the emergence of innovative techniques that can map the distribution of 5-hydroxymethylcytosine at high resolution. In the context of current epigenetic therapies and by using recent functional studies, we propose plausible mechanisms to target the 5-hydroxymethylcytosine pathway in cancer. As the study of 5-hydroxymethylcytosine is still in its infancy, we provide future perspectives.
Author supplied keywords
Cite
CITATION STYLE
Rodger, E. J., Chatterjee, A., & Morison, I. M. (2014, October 1). 5-hydroxymethylcytosine: A potential therapeutic target in cancer. Epigenomics. Future Medicine Ltd. https://doi.org/10.2217/epi.14.39
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.